Yang Ningning, Ye Zhaoyang, Li Feng, Mahato Ram I
Department of Pharmaceutical Sciences, University of Tennessee, Health Science Center, Memphis, Tennessee 38103, USA.
Bioconjug Chem. 2009 Feb;20(2):213-21. doi: 10.1021/bc800237t.
The objective was to determine whether bioconjugation of type I collagen specific triplex forming oligonucleotide (TFO) to N-(2-hydroxypropyl) methacrylamide (HPMA) containing tetrapeptide Gly-Phe-Leu-Gly (GFLG) and mannose 6-phosphate (M6P) can provide their targeted delivery to hepatic stellate cells (HSCs). Following bioconjugation, M6P-GFLG-HPMA-GFLG-32P-TFO was characterized by PAGE, HPLC, and GPC, and then its biodistribution was determined. TFO was dissociated from the conjugate when incubated with papain and formed triplex with the target DNA duplex. Type 1 collagen gene expression was significantly inhibited when HSC-T6 cells were transfected with this conjugate. Following tail vein injection into rats, M6P-GFLG-HPMA-GFLG-(32)P-TFO was rapidly cleared from the circulation and accumulated mainly in the liver. The plasma concentration versus time profile was biphasic, with 12.37 min as t(1/2) of distribution and 2886.48 min as t(1/2) of elimination. A large proportion of the injected M6P-GFLG-HPMA-GFLG-32P-TFO was taken up by the HSCs of both normal and fibrotic rats, which were isolated by liver perfusion at 30 min post-injection. Preinjection of M6P-GFLG-HPMA-GFLG-ONP into fibrotic rats decreased the liver uptake of the conjugates from 60% to 13%, suggesting M6P/TGFII receptor-mediated endocytosis of the conjugates by HSCs. Almost 80% of the total liver uptake in fibrotic rats was contributed by HSCs. In conclusion, conjugation with M6P-HPMA-GFLG significantly increased TFO delivery to the HSCs and could be potentially used for treating liver fibrosis.
目的是确定将I型胶原特异性三链形成寡核苷酸(TFO)与含有四肽甘氨酸-苯丙氨酸-亮氨酸-甘氨酸(GFLG)和甘露糖6-磷酸(M6P)的N-(2-羟丙基)甲基丙烯酰胺(HPMA)进行生物共轭是否能将它们靶向递送至肝星状细胞(HSC)。生物共轭后,通过聚丙烯酰胺凝胶电泳(PAGE)、高效液相色谱(HPLC)和凝胶渗透色谱(GPC)对M6P-GFLG-HPMA-GFLG-32P-TFO进行表征,然后测定其生物分布。当与木瓜蛋白酶一起孵育时,TFO从共轭物中解离出来,并与靶DNA双链体形成三链体。当用这种共轭物转染HSC-T6细胞时,I型胶原基因表达受到显著抑制。尾静脉注射到大鼠体内后,M6P-GFLG-HPMA-GFLG-(32)P-TFO迅速从循环中清除,主要积聚在肝脏中。血浆浓度-时间曲线呈双相,分布半衰期(t(1/2))为12.37分钟,消除半衰期为2886.48分钟。注射的M6P-GFLG-HPMA-GFLG-32P-TFO的很大一部分被正常和纤维化大鼠的肝星状细胞摄取,在注射后30分钟通过肝脏灌注分离得到这些细胞。向纤维化大鼠预先注射M6P-GFLG-HPMA-GFLG-ONP可使共轭物的肝脏摄取从60%降至13%,表明肝星状细胞通过M6P/转化生长因子II受体介导的内吞作用摄取共轭物。纤维化大鼠肝脏总摄取量的近80%由肝星状细胞贡献。总之,与M6P-HPMA-GFLG共轭显著增加了TFO向肝星状细胞的递送,并且可能潜在地用于治疗肝纤维化。